Can I Take Reishi Mushroom with Lantus (Insulin Glargine)?

What Is the Interaction Between Reishi Mushroom and Lantus?

The short answer is that combining reishi mushroom with Lantus introduces two overlapping risks: additive blood-sugar lowering and possible potentiation of anticoagulant effects. Neither interaction has been studied in a large randomized controlled trial specifically pairing reishi with insulin glargine. Most of what is known comes from smaller human studies on reishi alone, animal data, and clinical pharmacology reasoning.

Lantus is a long-acting basal insulin. It works by binding insulin receptors in muscle, fat, and liver tissue to lower circulating glucose over roughly 24 hours with a relatively flat activity profile. Reishi mushroom contains bioactive polysaccharides (notably beta-glucans), triterpenoids, and proteoglycans that appear to reduce blood glucose through several routes: increasing peripheral glucose uptake, inhibiting alpha-glucosidase activity in the gut, and possibly stimulating insulin secretion from pancreatic beta cells.

When you add a second glucose-lowering agent to basal insulin, the combined effect can push blood glucose lower than either agent would alone. That is the core concern.

Pharmacokinetic vs. Pharmacodynamic: Which Type of Interaction Is This?

This is predominantly a pharmacodynamic interaction. Reishi does not appear to meaningfully alter how insulin glargine is absorbed, distributed, or cleared from your body (that would be a pharmacokinetic interaction). Instead, both agents act on blood glucose through different but complementary mechanisms, and their effects add together at the level of the outcome: circulating glucose concentration.

A small pharmacokinetic consideration does exist. Some reishi triterpenoids show inhibitory activity toward cytochrome P450 enzymes in vitro, but insulin glargine is not metabolized by CYP enzymes, so this pathway is not considered clinically significant for this specific pairing.

How Strong Is the Blood-Sugar-Lowering Evidence for Reishi?

The human evidence for reishi as a glucose-lowering agent is modest but real. A 2016 systematic review and meta-analysis in the Journal of Ethnopharmacology examined five randomized controlled trials in people with type 2 diabetes and found that Ganoderma lucidum extract did not significantly reduce fasting plasma glucose or HbA1c compared with placebo across the pooled population, though some individual studies showed reductions. The heterogeneity in extract preparation, dose, and duration limited the meta-analysis. That uncertainty cuts both ways: the overall effect on glucose may be modest, but you cannot assume reishi is inert when you are already on a basal insulin that keeps you in a narrow glucose band.

Animal data, including a study published in Phytomedicine using diabetic mouse models, showed significant reductions in blood glucose with reishi polysaccharide fractions. Extrapolation from animal models to human clinical outcomes requires caution, and human studies in people already on insulin are essentially absent from the published literature. This is a genuine evidence gap, and you deserve to know it.

Why Women with Diabetes Face Specific Considerations

Women's metabolic physiology is not just a smaller version of male physiology. Insulin sensitivity, glucose regulation, and hypoglycemia risk all shift across the menstrual cycle, pregnancy, postpartum, and menopause. Any supplement that touches blood glucose deserves evaluation through that lens.

Reproductive Years and the Menstrual Cycle

Insulin sensitivity fluctuates across your cycle. During the luteal phase (roughly days 14 to 28), progesterone and estrogen together reduce insulin sensitivity, meaning your insulin requirements may be higher in the week before your period. If you add reishi during the follicular phase when insulin sensitivity is naturally higher, your hypoglycemia risk could be greater than you might expect based on your usual pattern.

Women with type 1 diabetes frequently report that blood glucose is harder to control in the luteal phase, and dose adjustments of 10 to 20 percent for basal insulin are sometimes needed. Reishi adds an unpredictable variable to an already variable system.

PCOS

Polycystic ovary syndrome affects approximately 8 to 13 percent of women of reproductive age and is characterized by insulin resistance. Some women with PCOS are prescribed insulin, or are on other glucose-lowering agents like metformin, and may also be drawn to complementary supplements marketed for blood sugar. If you have PCOS and are on insulin glargine, reishi is an additional agent that could shift your glucose balance in ways that are difficult to predict without monitoring.

Perimenopause and Post-Menopause

Estrogen has direct effects on insulin receptor sensitivity. As estrogen declines during perimenopause, insulin resistance typically increases. The Menopause Society (formerly NAMS) recognizes that the menopausal transition is associated with worsening metabolic parameters including glucose tolerance. Women who start reishi mushroom supplements during perimenopause for immune support, sleep, or hormone-adjacent marketing claims may not realize they are also adding a compound with glucose-modulating activity to a body that is already recalibrating its metabolic baseline.

Post-menopausal women on basal insulin should be particularly alert, because hypoglycemia symptoms (palpitations, sweating, tremor) can overlap with vasomotor symptoms, making it harder to recognize a low blood glucose episode without actually checking a number.

The Anticoagulant Concern: What You Should Know

Reishi mushroom contains triterpene acids and polysaccharide fractions that have demonstrated platelet aggregation inhibition in both in vitro studies and in small human studies. This is not a trivial secondary finding. If you take any other agent with anticoagulant or antiplatelet activity alongside reishi, you may have an additive bleeding risk.

Insulin glargine itself does not have anticoagulant properties, so the direct pairing of Lantus plus reishi does not create an anticoagulant interaction. The concern is indirect: many women with diabetes also take aspirin for cardiovascular protection, or are on anticoagulants for atrial fibrillation or clotting disorders. Reishi added to that background regimen could increase bleeding risk.

A simple three-question framework before starting reishi helps clarify your personal risk level:

1. Are you on any anticoagulant or antiplatelet agent (warfarin, apixaban, rivaroxaban, aspirin, clopidogrel)?
2. Do you have a surgery or procedure scheduled within four weeks?
3. Are you pregnant or planning to become pregnant?

If you answer yes to any of these, you should not start reishi without direct guidance from your prescriber.

Mechanism Deep Dive: How Reishi May Lower Blood Sugar

Understanding the mechanism helps you and your care team make a more informed decision rather than treating this as a simple yes-or-no.

Alpha-Glucosidase Inhibition

Reishi polysaccharides and some triterpenoids inhibit alpha-glucosidase, an intestinal enzyme that breaks down complex carbohydrates into absorbable simple sugars. This slows postprandial glucose absorption. Research published in Food Chemistry identified alpha-glucosidase inhibitory activity in Ganoderma lucidum extracts, with activity comparable in direction (though not magnitude) to the pharmaceutical drug acarbose. Because Lantus is a basal insulin managing fasting glucose rather than postprandial spikes, this mechanism has less direct overlap, but it still contributes to the overall glucose-lowering picture.

Beta-Cell and Insulin Secretion Effects

Some reishi polysaccharide fractions appear to stimulate insulin secretion from pancreatic beta cells in animal models. For women with type 1 diabetes, who have near-total beta-cell loss, this mechanism is not operational. For women with type 2 diabetes or PCOS-related insulin resistance with residual beta-cell function, it is a relevant additional mechanism that could contribute to hypoglycemia when combined with exogenous insulin.

Peripheral Glucose Uptake

Reishi polysaccharides may activate AMPK pathways in muscle cells, increasing glucose uptake independently of insulin. AMPK activation is also the primary mechanism of metformin. A woman already on basal insulin who adds an AMPK-activating supplement is effectively adding a second mechanism of glucose disposal. The published animal data on AMPK activation by Ganoderma polysaccharides is intriguing but has not been replicated in adequately powered human studies.

Monitoring: What to Actually Do If You Are Already Taking Both

If you are currently taking both Lantus and reishi mushroom and did not realize there was a potential interaction, do not panic and do not stop either abruptly without guidance. Here is a practical monitoring approach.

Check your fasting blood glucose every morning for at least two weeks if you have recently started reishi. Write the numbers down. If you are seeing fasting readings below 70 mg/dL more than twice per week, contact your prescriber. The American Diabetes Association defines hypoglycemia as a blood glucose level below 70 mg/dL, with clinically significant hypoglycemia defined as below 54 mg/dL.

Signs of hypoglycemia to watch for include:

• Shakiness or trembling
• Sweating (distinct from a hot flash in perimenopausal women)
• Heart pounding or racing
• Confusion or difficulty concentrating
• Headache on waking
• Hunger that feels urgent

If you experience any of these symptoms, check your glucose immediately. Treat with 15 grams of fast-acting carbohydrate (4 ounces of juice, glucose tablets), wait 15 minutes, and recheck. If glucose is still below 70 mg/dL, treat again and call your care team.

Do not adjust your Lantus dose on your own to accommodate the addition of reishi. That conversation needs to happen with your prescriber.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, planning pregnancy, or breastfeeding.

Insulin Glargine in Pregnancy

Insulin is the preferred pharmacological treatment for diabetes in pregnancy. ACOG Practice Bulletin No. 201 on gestational diabetes and ACOG Practice Bulletin No. 60 on pregestational diabetes both support insulin as first-line when medication is needed. Insulin glargine (Lantus) is a long-acting analog. While NPH insulin has the longest safety record in pregnancy, growing observational data support glargine as a reasonable option. A 2015 meta-analysis in Diabetes Care found no significant difference in neonatal outcomes between insulin glargine and NPH in pregnant women. Insulin does not cross the placenta in meaningful quantities at physiological doses.

Do not stop insulin glargine in pregnancy if you are on it for type 1 or type 2 diabetes. Uncontrolled diabetes in pregnancy carries serious risks for both you and the fetus, including congenital anomalies in the first trimester and macrosomia, stillbirth, and preeclampsia at later stages.

Reishi Mushroom in Pregnancy

Reishi mushroom should not be used during pregnancy. There are no adequate human safety data in pregnant women. Animal reproductive toxicity studies are insufficient to rule out harm. The Natural Medicines Database rates reishi as "Possibly Unsafe" in pregnancy based on insufficient evidence and theoretical risks. Given that the glucose-lowering effects of reishi could contribute to hypoglycemia at a time when stable glucose control is essential for fetal development, the risk-benefit calculation clearly favors avoidance. If you are currently taking reishi and discover you are pregnant, stop immediately and inform your obstetrician and diabetes care team.

Lactation

Human data on reishi transfer into breast milk are absent from the published literature. Until proven safe, reishi mushroom should not be used during breastfeeding. Insulin glargine, by contrast, is compatible with breastfeeding. Insulin is a protein that is largely degraded in the infant's gut if any does pass into milk, and no adverse infant effects have been documented.

Contraception Note

If you are on insulin glargine for type 2 diabetes and are not planning pregnancy, be aware that reliable contraception is important because unplanned pregnancy in poorly controlled diabetes carries higher risks. Your prescriber can discuss contraceptive options that do not worsen insulin resistance. Combined hormonal contraceptives containing progestin can reduce insulin sensitivity; progestin-only methods and non-hormonal options may be preferable depending on your metabolic profile.

Who This Combination Is Not Right For

Some situations make the Lantus-reishi combination particularly inadvisable:

• Type 1 diabetes on a fixed Lantus dose. Your glucose is maintained in a narrow window. Adding a supplement with uncertain glucose-lowering potency is an unnecessary variable.
• Frequent hypoglycemia already. If you are already experiencing lows, you do not need another agent that may drive glucose down further.
• Pregnancy or planning to conceive. Reishi is not safe in pregnancy. Full stop.
• Concurrent anticoagulant therapy. Warfarin, apixaban, rivaroxaban, clopidogrel, or even daily high-dose aspirin combined with reishi raises bleeding risk.
• Upcoming surgery within four weeks. Reishi should be stopped at least two weeks before any surgical procedure due to antiplatelet effects.
• Liver disease. Several case reports have linked high-dose reishi supplements to hepatotoxicity. A case series published in Hepatology documented liver injury attributed to reishi powder, and the potential for liver toxicity is a genuine concern at high doses or with contaminated products.

Who Might Reasonably Discuss This with Their Doctor

A smaller group of women might have a conversation about reishi that their prescriber considers low-risk:

• Women with well-controlled type 2 diabetes on a stable Lantus dose who are not on anticoagulants, are not pregnant, and who commit to frequent glucose monitoring.
• Women who are using reishi at a low culinary dose (as in whole mushroom in food rather than concentrated extract capsules), where the pharmacological effect may be minimal.

Even in these situations, the answer is not a self-directed "yes." It is a conversation that leads to a documented monitoring plan.

Dose Timing and Practical Notes

No established dose-separation window exists for reishi and insulin, because the interaction is pharmacodynamic (about effect, not absorption). Separating them by two hours in timing does not meaningfully reduce the additive glucose-lowering risk. The only reliable mitigation strategy is closer glucose monitoring and a willingness to adjust the Lantus dose under medical supervision if needed.

If your prescriber decides the combination is acceptable for your situation, the practical steps are:

1. Start reishi at the lowest available dose, not the maximum.
2. Check fasting glucose daily for the first three weeks.
3. Log any glucose readings below 80 mg/dL and report them.
4. Bring your glucose log to your next appointment.
5. Stop reishi at least two weeks before any planned surgery or invasive procedure.

The American Diabetes Association Standards of Care in Diabetes 2024 recommend that clinicians ask about all dietary supplements at every diabetes visit, precisely because interactions like this one go unreported when patients assume supplements are automatically safe.

A Note on Product Quality

The supplement market for reishi in the United States is unregulated for efficacy and only loosely regulated for safety. The dose of active polysaccharides and triterpenoids varies widely between products, and some contain contaminants including heavy metals. Look for products certified by NSF International or USP (United States Pharmacopeia), which verify label accuracy and contaminant testing. Third-party certification does not guarantee efficacy, but it does reduce your exposure to unknown adulterants that could add further unpredictable drug interactions.